共 50 条
- [21] Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (08): : 495 - 500
- [22] SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : 573 - 582
- [23] "Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (05): : 301 - 310
- [24] SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (04): : 238 - 243
- [25] SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : 649 - 652
- [26] SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04): : 226 - 239
- [27] SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 340 - 347
- [28] SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (10): : 705 - 713
- [29] SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (01): : 1 - 7
- [30] SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09): : 633 - 641